Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly
Crossref DOI link: https://doi.org/10.1007/s12185-017-2333-y
Published Online: 2017-09-27
Published Print: 2018-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kirito, Keita
Suzuki, Kenshi
Miyamura, Koichi
Takeuchi, Masahiro
Handa, Hiroshi
Okamoto, Shinichiro
Gadbaw, Brian
Yamauchi, Kyosuke
Amagasaki, Taro
Ito, Kazuo
Hino, Masayuki
Funding for this research was provided by:
Novartis Pharma KK
License valid from 2017-09-27